Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MIR194-2 host gene (MIR194-2HG)
- Target
- MIR194-2HG
- Molecular classification
- Other (long non-coding RNA gene; host gene for microRNAs)
01
Overview
MIR194-2 host gene (MIR194-2HG) is a long noncoding RNA gene that encodes the primary transcript for microRNAs miR-194-2 and miR-192, which are processed and function as regulatory molecules in multiple cancer types[2][3]. These miRNAs, particularly miR-194, play tumor-suppressive roles by downregulating genes essential for cell proliferation and migration, such as ATP6V1F, PPP1R14B, BTF3L4, and SLC7A5 in gastrointestinal cancers[1]. Expression of MIR194-2HG and its associated miRNAs is tissue-specific, with selective enrichment in liver, colorectal, and gastric tissues[1]. Changes in MIR194-2HG or its hosted miRNAs affect cancer progression, prognosis, cell migration, apoptosis, and response to chemotherapy[1][2][3]. While not a conventional drug target, its regulatory influence via hosted miRNAs makes it an important molecule in cancer biology, biomarker development, and experimental RNA-based therapeutics[1][2][3].
- Other names
- MIR194-2HGPri-microRNA-194-2 host genePri-microRNA-194-2, -192Long noncoding RNA MIR194-2HG
02
Mechanism of action
Epigenetic regulation (expression of MIR194-2HG can be modified, leading to downstream changes in miR-194-2, miR-192 activity); RNA interference approaches (experimental, targeting the host gene to release or suppress miRNA activity)
03
Biological functions
Regulation of microRNA production (miR-194-2, miR-192)Tumor suppression via downregulation of oncogenic targets (mediated by hosted miRNAs)Cell proliferation inhibitionApoptosis (indirectly, via hosted miRNAs)Regulation of cell migration and invasion
04
Disease associations
Cancer (especially gastrointestinal cancers, colorectal, gastric, liver, lung, and triple-negative breast cancer)Tumor progression and suppressionChemosensitivity (non-small cell lung cancer)
05
Safety considerations
As a gene and indirect target, there are no direct safety concerns. For interventions targeting MIR194-2HG, off-target effects due to global microRNA changes and downstream effects must be carefully evaluated, especially in RNA therapeutics
06
Interacting drugs
No conventional drugs directly interact with MIR194-2HG as a host gene. However, RNA-based therapies, and possibly histone deacetylase inhibitors (by epigenetic modulation of host gene expression), may have indirect effects
07
Biomarkers
miR-194 (hosted by MIR194-2HG) is an optimal biomarker for prognosis in gastrointestinal cancers, correlating with overall survival, disease-specific survival, and progression-free intervalsmiR-192 (hosted) is relevant as a biomarker in triple-negative breast cancer
Beyond the preview
Go deeper on MIR194-2 host gene (MIR194-2HG).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIR194-2 host gene (MIR194-2HG).